CORRECTING and REPLACING -- FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4
March 31, 2017 15:44 ET
|
FLX Bio
In a release issued under the same headline earlier today by FLX Bio, Inc., please note that the link to the abstract title under the Abstract information section was incorrect and has...
FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4
March 31, 2017 11:00 ET
|
FLX Bio
SOUTH SAN FRANCISCO, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology (IO) agents and...
FLX Bio, Inc. Appoints Linda Kozick to its Board of Directors
December 12, 2016 12:42 ET
|
FLX Bio
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today...
FLX Bio Announces $50 Million Series B Financing
April 26, 2016 12:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 26, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced a $50...
FLX Bio Completes Leadership Team in Immuno-Oncology Drug Discovery
April 05, 2016 11:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today...
FLX Bio Hires Senior Leaders in Immuno-Oncology Drug Discovery
February 08, 2016 11:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced...